Thesis (Ph. D.)--University of Missouri-Columbia, 2006. / The entire dissertation/thesis text is included in the research.pdf file; the official abstract appears in the short.pdf file (which also appears in the research.pdf); a non-technical general description, or public abstract, appears in the public.pdf file. Title from title screen of research.pdf file viewed on (March 3, 2007) Vita. Includes bibliographical references.

Thesis (Ph.D.)--Ohio University, March, 2006. / Includes bibliographical references (leaves 152-160)

Neuroinflammation occurs in Alzheimer’s disease (AD) brain, and plays a role in neurodegeneration. The main aim of this study was to determine how treatments with exogenous apolipoprotein E (ApoE2, E3 and E4 isoforms), a genetic risk factor for AD, affects the amyloid-β (Aβ) induced inflammatory response in vitro in astrocytes. Recombinant, lipid-free ApoE4 was found not to affect Aβ-induced inflammation in rat astrocytes, while ApoE2 showed a protective effect. Mouse cells expressing human ApoE isoforms, which have similar lipidation and modification to native human ApoE, showed ApoE4 promoting inflammation, and no ApoE2 protective effect upon Aβ treatment. A Protein/DNA array was used to screen 345 transcription factors in rat astrocytes treated with Aβ and/or ApoE isoforms, in order to determine which contribute to the observed ApoE2 protection. Some candidates were validated by Western Blot or EMSA and/or by inhibition or activation. The findings suggest ApoE isoforms differentially regulate Aβ-induced inflammation, and multiple signalling pathways are involved in the process.

Presenilin-1 (PS-1) is the catalytic core of the ã-secretase complex, which is best known for its role in the generation of the Alzheimer disease (AD)-related â-amyloid peptide. Mutated forms of PS-1 are known to be associated with particularly aggressive forms of AD. Changes in monoaminergic neurotransmitter systems, including the serotonin and norepinephrine systems, have long been associated with some of the earliest events in AD, whereas changes in the availability of these same monoamines have historically been associated with clinical depression. Therefore, it is not surprising that depression has now been proposed as a risk factor for developing AD and that pre-demented carriers of mutated forms of PS-1 are more prone to developing depression. MAO-A is historically associated with depression and is also a known risk factor for AD. Given this, I hypothesized that MAO-A represents a neurochemical link between depression and AD, and I chose to examine the influence of PS-1 mutations on MAO-A function in vivo/ex vivo and in vitro.<p> I first focused on the PS-1(M146V) knock-in mouse model of AD-related PS-1/ã-secretase function. I used a radioenzymatic assay to estimate MAO-A catalytic activity and western blot analysis to determine MAO-A protein expression, and found that MAO-A activity does not correlate with MAO-A expression in the cortex and cerebellum of the PS-1(M146V) mice. Furthermore, the potency of the MAO-A inhibitor clorgyline (CLG) is greater in both the cortex and cerebellum of the PS-1(M146V) mice compared to the potency of CLG in wildtype littermates. CLG dose-response curves suggest that there might be a change in cooperativity in the MAO-A protein from PS-1(M146V) cortex (which would suggest a change in conformation and/or access of the substrate to the catalytic pocket in MAO-A). High-pressure liquid chromatography was used to analyze monoamine levels in these same regions. The levels of monoamines (i.e. serotonin, dopamine and norepinephrine) suggest that PS-1 (M146V) inhibits MAO-A function in the cortex, but not in the cerebellum. Furthermore, CLG has no significant effect on amine levels in cortex, but tends to increase their accumulation in cerebellum.<p> The overexpression of PS-1 (M146V) in neuronal cultures reveals that this protein affects MAO-A activity and, more importantly, the PS-1(M146V) protein co-precipitates with MAO-A, thus suggesting a possibility for a direct protein-protein interaction. This is supported by the observation that MAO-A activity is increased in cell extracts incubated with the PS-1 substrate-competitor, N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT). Preliminary studies have been undertaken to determine the motif in MAO-A that could be acting as a binding site/target site for PS-1.<p> These combined results support the hypothesis that PS-1 proteins can influence MAO-A function and, furthermore, that MAO-A is a novel interactor for PS-1/ã-secretase. This could well explain some of the ambiguous literature associated with both of these proteins in disorders as diverse as depression and AD.

scyllo-Inositol is currently in phase II clinical trials as a therapeutic for Alzheimer’s disease (AD). Previous work from our lab has shown that scyllo-inositol prevents Ab1-42 fibril formation instead leading to the formation of small Ab oligomers in vitro. To further understand the molecular details of Ab-scyllo-inositol binding interactions, a library of scyllo-inositol derivatives was prepared. A sequence of protecting group transformations afforded a hydroxylamine functionalized scyllo-inositol. Subsequent oxime formation with aromatic aldehydes generated a novel class of inositol derivatives in good yield and high purity. The effects of these compounds on the Ab aggregation cascade were evaluated by a biotin-avidin Ab1-42 oligomer assay and atomic force microscopy (AFM). Preliminary plate assay data indicated that several of these derivatives increased peptide oligomerization and the corresponding AFM images showed altered fibril formation. These results suggested that this class of scyllo-inositol derivatives is active in the Ab aggregation cascade.

scyllo-Inositol is currently in phase II clinical trials as a therapeutic for Alzheimer’s disease (AD). Previous work from our lab has shown that scyllo-inositol prevents Ab1-42 fibril formation instead leading to the formation of small Ab oligomers in vitro. To further understand the molecular details of Ab-scyllo-inositol binding interactions, a library of scyllo-inositol derivatives was prepared. A sequence of protecting group transformations afforded a hydroxylamine functionalized scyllo-inositol. Subsequent oxime formation with aromatic aldehydes generated a novel class of inositol derivatives in good yield and high purity. The effects of these compounds on the Ab aggregation cascade were evaluated by a biotin-avidin Ab1-42 oligomer assay and atomic force microscopy (AFM). Preliminary plate assay data indicated that several of these derivatives increased peptide oligomerization and the corresponding AFM images showed altered fibril formation. These results suggested that this class of scyllo-inositol derivatives is active in the Ab aggregation cascade.

Most persons with a dementia are cared for in the home by family members who experience a broad and considerable amount of stress and whose caregiving careers may include planning for or initiating moves to memory care units (MCUs). This study examines the decision-making processes of primary informal caregivers regarding their care recipients' moves to MCUs. Grounded theory methods were used to collect and analyze data in two long-term care (LTC) facilities varying in characteristics including capacity, state licensure, fees, and resident profiles. Specific aims are two-fold: 1) advance an understanding of how primary informal caregivers of persons with a dementia made decisions for formal memory care, and 2) identify the important factors related to the decision-making process.

Presenilin-1 (PS-1) is the catalytic core of the ã-secretase complex, which is best known for its role in the generation of the Alzheimer disease (AD)-related â-amyloid peptide. Mutated forms of PS-1 are known to be associated with particularly aggressive forms of AD. Changes in monoaminergic neurotransmitter systems, including the serotonin and norepinephrine systems, have long been associated with some of the earliest events in AD, whereas changes in the availability of these same monoamines have historically been associated with clinical depression. Therefore, it is not surprising that depression has now been proposed as a risk factor for developing AD and that pre-demented carriers of mutated forms of PS-1 are more prone to developing depression. MAO-A is historically associated with depression and is also a known risk factor for AD. Given this, I hypothesized that MAO-A represents a neurochemical link between depression and AD, and I chose to examine the influence of PS-1 mutations on MAO-A function in vivo/ex vivo and in vitro.<p> I first focused on the PS-1(M146V) knock-in mouse model of AD-related PS-1/ã-secretase function. I used a radioenzymatic assay to estimate MAO-A catalytic activity and western blot analysis to determine MAO-A protein expression, and found that MAO-A activity does not correlate with MAO-A expression in the cortex and cerebellum of the PS-1(M146V) mice. Furthermore, the potency of the MAO-A inhibitor clorgyline (CLG) is greater in both the cortex and cerebellum of the PS-1(M146V) mice compared to the potency of CLG in wildtype littermates. CLG dose-response curves suggest that there might be a change in cooperativity in the MAO-A protein from PS-1(M146V) cortex (which would suggest a change in conformation and/or access of the substrate to the catalytic pocket in MAO-A). High-pressure liquid chromatography was used to analyze monoamine levels in these same regions. The levels of monoamines (i.e. serotonin, dopamine and norepinephrine) suggest that PS-1 (M146V) inhibits MAO-A function in the cortex, but not in the cerebellum. Furthermore, CLG has no significant effect on amine levels in cortex, but tends to increase their accumulation in cerebellum.<p> The overexpression of PS-1 (M146V) in neuronal cultures reveals that this protein affects MAO-A activity and, more importantly, the PS-1(M146V) protein co-precipitates with MAO-A, thus suggesting a possibility for a direct protein-protein interaction. This is supported by the observation that MAO-A activity is increased in cell extracts incubated with the PS-1 substrate-competitor, N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT). Preliminary studies have been undertaken to determine the motif in MAO-A that could be acting as a binding site/target site for PS-1.<p> These combined results support the hypothesis that PS-1 proteins can influence MAO-A function and, furthermore, that MAO-A is a novel interactor for PS-1/ã-secretase. This could well explain some of the ambiguous literature associated with both of these proteins in disorders as diverse as depression and AD.

Thesis (Ph. D.)Open University. BLDSC no. DXN036583.

Thesis (Ph. D.)--University of Hong Kong, 2001. / Includes bibliographical references (leaves 121-158).